Related Experiment Videos
[Endocrinological aspects of long-term lithium therapy]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|February 1, 1981
Summary
Long-term lithium treatment, when carefully dosed, shows no significant impact on cortisol, insulin, growth hormone, or glucose levels in patients with cyclophrenia, atypical psychosis, and schizophrenia. This finding supports the safety of lithium in managing these conditions.
Area of Science:
- Endocrinology
- Psychiatry
- Pharmacology
Background:
- Cyclophrenia, atypical psychosis, and schizophrenia are complex psychiatric conditions.
- Long-term treatment often involves neuroleptics, with lithium carbonate sometimes used as an adjunct therapy.
- Understanding the endocrine effects of long-term lithium use is crucial for patient management.
Purpose of the Study:
- To investigate the effects of long-term lithium carbonate treatment on endocrine parameters in patients with psychiatric disorders.
- To compare endocrine profiles between patients treated with lithium and neuroleptics versus those treated with neuroleptics alone.
- To assess the influence of lithium on cortisol and growth hormone (GH) secretion following insulin stimulation.
Main Methods:
- Study included three groups of 30 participants each: a control group, a psychiatric group treated with lithium carbonate and neuroleptics, and a psychiatric group treated only with neuroleptics.
- Blood serum levels of cortisol, insulin, somatotropin (GH), and lithium were measured.
- Fasting blood glucose levels were determined.
- Insulin tolerance tests were performed to examine cortisol and GH response.
Main Results:
- Long-term treatment with lithium carbonate, when doses were carefully selected, did not result in significant alterations in cortisol, insulin, somatotropin (GH), or glucose levels.
- No significant differences were observed in these parameters between the lithium-treated group and the neuroleptic-only group.
- Lithium's influence on cortisol and GH secretion post-insulin stimulation was also found to be non-significant.
Conclusions:
- Carefully managed, long-term lithium therapy appears safe concerning the examined endocrine parameters in patients with cyclophrenia, atypical psychosis, and schizophrenia.
- The study suggests that lithium does not adversely affect key hormonal balances or glucose metabolism in these patient populations.
- These findings support the continued use of lithium as a therapeutic option when indicated, with appropriate monitoring.